I had a look at the annual report today and try to foresee what may be the range of the net profit for next year. Thought that I may be able to look for some value here..
If we believe a lot of the industry's talks about generic drug deflation being in the high single digit. Let's say 10% deflation. This will essentially shaved off $42M of gross profit(straight off the bottom line everything else being equal) for MYX assuming same revenue sales in generics division . The other 2 divisions, i.e. MCS and Specialty Brands have combined $90M Gross Profit for FY17. For MYX to maintain same net profit as per FY17, these 2 divisions need to increase by 50%. Not only that, this year's NPAT included $33M gross profit from once-off items. So, to maintain FY17 NPAT, the other divisions need to almost double their profit (i.e. increase by 42+33 = $75M) to make up for the generic drug price deflation impact.
Not a good position to be in indeed for MYX..
- Forums
- ASX - By Stock
- MYX
- Fundamentals Are Strong
Fundamentals Are Strong, page-849
-
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.95 |
Change
0.000(0.00%) |
Mkt cap ! $333.4M |
Open | High | Low | Value | Volume |
$3.96 | $3.96 | $3.89 | $255.6K | 65.42K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 478 | $3.95 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.96 | 1641 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 225 | 3.950 |
9 | 2755 | 3.940 |
7 | 1847 | 3.930 |
6 | 1355 | 3.920 |
7 | 1446 | 3.910 |
Price($) | Vol. | No. |
---|---|---|
3.960 | 1096 | 9 |
3.970 | 1332 | 5 |
3.980 | 4784 | 8 |
3.990 | 13421 | 4 |
4.000 | 1674 | 4 |
Last trade - 11.51am 07/08/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |